Evidence map›Paper›PMID 34600479›Full record

ArticleBMC bioinformatics2021

DECONbench: a benchmarking platform dedicated to deconvolution methods for tumor heterogeneity quantification.

Clémentine Decamps, Alexis Arnaud, Florent Petitprez, Mira Ayadi, Aurélia Baurès, Lucile Armenoult, HADACA consortium, Sergio Escalera, Isabelle Guyon, Rémy Nicolle and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Clémentine Decamps *Laboratory TIMC-IMAG, UMR 5525, CNRS, Univ. Grenoble Alpes, Grenoble, France.
Alexis Arnaud *Data Institute, Univ. Grenoble Alpes, Grenoble, France.
Florent PetitprezProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
Mira AyadiProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
Aurélia BaurèsProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
Lucile ArmenoultProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
HADACA consortium
Sergio EscaleraUniversitat de Barcelona and Computer Vision Center, Barcelona, Spain.
Isabelle GuyonLISN (INRIA/CNRS), Université Paris-Saclay, Gif-sur-Yvette, France.
Rémy NicolleProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
Richard TomasiniINSERM U1068 CRCM, Marseille, France.
Aurélien de ReynièsProgramme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France.
Jérôme CrosDpt of Pathology, Beaujon Hospital, Univ. Paris-INSERM U1149, Clichy, France.
Yuna Blum *Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France. yuna.blum@univ-rennes1.fr.ORCID http://orcid.org/0000-0002-4716-8017
Magali Richard *Laboratory TIMC-IMAG, UMR 5525, CNRS, Univ. Grenoble Alpes, Grenoble, France. magali.richard@univ-grenoble-alpes.fr.
La Ligue Contre le Cancer · FRCentre National de la Recherche Scientifique · FRCenter for Research and Interdisciplinarity · FRInserm · FRCentre de Recherche en Cancérologie de Marseille · FRInstitut de génétique et de développement de Rennes · FRUniversité Grenoble Alpes · FRComputer Vision Center

Funding

EIT Health 20377EIT Health activities 19359Université Grenoble Alpes ANR-15-IDEX-02
6 · The paper itself

Abstract

backgroundQuantification of tumor heterogeneity is essential to better understand cancer progression and to adapt therapeutic treatments to patient specificities. Bioinformatic tools to assess the different cell populations from single-omic datasets as bulk transcriptome or methylome samples have been recently developed, including reference-based and reference-free methods. Improved methods using multi-omic datasets are yet to be developed in the future and the community would need systematic tools to perform a comparative evaluation of these algorithms on controlled data.

resultsWe present DECONbench, a standardized unbiased benchmarking resource, applied to the evaluation of computational methods quantifying cell-type heterogeneity in cancer. DECONbench includes gold standard simulated benchmark datasets, consisting of transcriptome and methylome profiles mimicking pancreatic adenocarcinoma molecular heterogeneity, and a set of baseline deconvolution methods (reference-free algorithms inferring cell-type proportions). DECONbench performs a systematic performance evaluation of each new methodological contribution and provides the possibility to publicly share source code and scoring.

conclusionDECONbench allows continuous submission of new methods in a user-friendly fashion, each novel contribution being automatically compared to the reference baseline methods, which enables crowdsourced benchmarking. DECONbench is designed to serve as a reference platform for the benchmarking of deconvolution methods in the evaluation of cancer heterogeneity. We believe it will contribute to leverage the benchmarking practices in the biomedical and life science communities. DECONbench is hosted on the open source Codalab competition platform. It is freely available at: https://competitions.codalab.org/competitions/27453 .

Indexed as

AdenocarcinomaPancreatic NeoplasmsAlgorithmsBenchmarkingComputational BiologyHumansBenchmarking platformCancerCellular heterogeneityDeconvolutionDNA methylationOmics integrationTranscriptome

Identifiers

PMID34600479
PMCPMC8487526
OpenAlexW3202268458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.